ARCHIVES

ODAC Unanimously Rejects Melblez, Citing Lower Survival

This article is from The Cancer Letter archive.

Vol. 39 No. 20 | May 17, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI Grants Get More Money, Pay Line Boosted To 193

May 22, 1981

FDA Says ImClone Data Insufficient To Evaluate Colorectal Cancer Drug C225.

January 4, 2002

In Brief : Patricia LoRusso Named Associate Director Of Innovative Medicine at Yale Cancer Center

June 20, 2014

Lines Drawn Over HHS Appropriations.

October 5, 2007

In Brief: Howley, Simone Lead Cancer Policy Board: AMA Campaign Fights Youth Smoking

November 22, 1996

Market Forces Changing Health Care System, Oncologists Told

June 2, 1995